Atossa Therapeutics (ATOS)
NASDAQ:ATOS
Want to see ATOS full AI Analyst Report?
Total Valuation
Atossa Therapeutics has a market cap or net worth of $42.71M. The enterprise value is $10.99M.
Market Cap$42.71M
Enterprise Value$10.99M
Share Statistics
Atossa Therapeutics has 8,611,361 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding8,611,361
Owned by Insiders2.51%
Owned by Institutions<0.01%
Financial Efficiency
Atossa Therapeutics’s return on equity (ROE) is -0.88 and return on invested capital (ROIC) is -94.38%.
Return on Equity (ROE)-0.88
Return on Assets (ROA)-0.73
Return on Invested Capital (ROIC)-94.38%
Return on Capital Employed (ROCE)-0.94
Revenue Per Employee0.00
Profits Per Employee-2.32M
Employee Count15
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Atossa Therapeutics is ―. Atossa Therapeutics’s PEG ratio is -0.06.
PE Ratio―
PS Ratio0.00
PB Ratio1.94
Price to Fair Value1.94
Price to FCF-2.56
Price to Operating Cash Flow-1.28
PEG Ratio-0.06
Income Statement
In the last 12 months, Atossa Therapeutics had revenue of 0.00 and earned -34.77M in profits. Earnings per share was -4.04.
Revenue0.00
Gross Profit-16.00K
Operating Income-37.14M
Pretax Income-34.77M
Net Income-34.77M
EBITDA-37.13M
Earnings Per Share (EPS)-4.04
Cash Flow
In the last 12 months, operating cash flow was -33.38M and capital expenditures -14.00K, giving a free cash flow of -33.40M billion.
Operating Cash Flow-33.38M
Free Cash Flow-33.40M
Free Cash Flow per Share-3.88
Dividends & Yields
Atossa Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.97
52-Week Price Change-59.42%
50-Day Moving Average5.30
200-Day Moving Average9.21
Relative Strength Index (RSI)42.56
Average Volume (3m)1.16M
Important Dates
Atossa Therapeutics upcoming earnings date is Aug 17, 2026, TBA (Confirmed).
Last Earnings DateMay 8, 2026
Next Earnings DateAug 17, 2026
Ex-Dividend Date―
Financial Position
Atossa Therapeutics as a current ratio of 5.53, with Debt / Equity ratio of 0.00%
Current Ratio5.53
Quick Ratio5.53
Debt to Market Cap0.00
Net Debt to EBITDA1.11
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Atossa Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Atossa Therapeutics EV to EBITDA ratio is -0.94, with an EV/FCF ratio of -1.17.
EV to Sales0.00
EV to EBITDA-0.94
EV to Free Cash Flow-1.17
EV to Operating Cash Flow-1.17
Balance Sheet
Atossa Therapeutics has $31.72M in cash and marketable securities with $0.00 in debt, giving a net cash position of $31.72M billion.
Cash & Marketable Securities$31.72M
Total Debt$0.00
Net Cash$31.72M
Net Cash Per Share$3.68
Tangible Book Value Per Share$4.57
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Atossa Therapeutics is $23.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$23.00
Price Target Upside294.51% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast-40.23%